This project has been archived.

4β-Hydroxycholesterol Working Group

The objective of the Working Group is to determine the validity, value and deployment of 4β-hydroxycholesterol as an endogenous minimally invasive biomarker of CYP3A activity and identification of drug candidates that modulate CYP3A activity (induction and inhibition) in clinical studies.  The Working Group will present its findings to the DMLG and CPLG and in a position paper to be shared among IQ member companies.  If the findings of the WG support the above objective, then this position will be communicated to drug regulatory authorities in order to gain acceptance of the assay for use in drug development.    

Delivery to date

Academic Sub-team

Bioanalytical Sub-team

Biology Sub-Team